1. Scrip
  2. >>Business
  3. >>Earnings

Lilly, With Tirzepatide Supply Issues Addressed, Raises Guidance By $3bn

Obesity, Diabetes Blockbusters Lead 36% Revenue Growth

 
• By Joseph Haas

Lilly now expects to bring in between $45.4bn and $46.6bn in total revenue this year, thanks mainly to continued growth for Mounjaro and Zepbound.

Lilly corporate center
Lilly posted 36% year-over-year growth during Q2 2024 • Source: Shutterstock

Eli Lilly and Company said supply issues for its GLP-1/GIP dual agonist tirzepatide – the active ingredient in type 2 diabetes drug Mounjaro and obesity treatment Zepbound – largely have been resolved. The company increased its full-year overall sales guidance for 2024 by $3bn when it reported second quarter earnings on 8 August, largely on the strength of those two products, but with some contribution from its breast cancer drug Verzenio (abemaciclib).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

AstraZeneca Logs Japan Growth Despite Price Cuts

 
• By Lisa Takagi

AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.

Taxes, Not Tariffs, Influence US Manufacturing, J&J CEO Says

 
• By Jessica Merrill

The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Regulatory And Macroeconomic Uncertainty Hang Over Q1 Earnings Season

 
• By Jessica Merrill

As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.

More from Business

The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Scrip about the latest developments.

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome

 
• By Joseph Haas

Plus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.

Taxes, Not Tariffs, Influence US Manufacturing, J&J CEO Says

 
• By Jessica Merrill

The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.